Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9375MR)

This product GTTS-WQ9375MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9375MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3887MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ7816MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ7339MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ13376MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1816MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1343MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ3209MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ1418MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACA125
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW